{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:43:09Z","timestamp":1790106189944,"version":"4.0.1"},"reference-count":135,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI126601"],"award-info":[{"award-number":["AI126601"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI148913"],"award-info":[{"award-number":["AI148913"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Significant advancement has been made in the development of vaccines against bacterial pathogens. However, several roadblocks have been found during the evaluation of vaccines against intracellular bacterial pathogens. Therefore, new lessons could be learned from different vaccines developed against unrelated intracellular pathogens. Bacillary dysentery and melioidosis are important causes of morbidity and mortality in developing nations, which are caused by the intracellular bacteria Shigella and Burkholderia pseudomallei, respectively. Although the mechanisms of bacterial infection, dissemination, and route of infection do not provide clues about the commonalities of the pathogenic infectious processes of these bacteria, a wide variety of vaccine platforms recently evaluated suggest that in addition to the stimulation of antibodies, identifying protective antigens and inducing T cell responses are some additional required elements to induce effective protection. In this review, we perform a comparative evaluation of recent candidate vaccines used to combat these two infectious agents, emphasizing the common strategies that can help investigators advance effective and protective vaccines to clinical trials.<\/jats:p>","DOI":"10.3390\/pathogens10111353","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T21:31:26Z","timestamp":1634765486000},"page":"1353","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Recent Progress in Shigella and Burkholderia pseudomallei Vaccines"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7878-4499","authenticated-orcid":false,"given":"Itziar","family":"Chapartegui-Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bowser","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-0643","authenticated-orcid":false,"given":"Alfredo G.","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA"},{"name":"Department of Pathology, University of Texas Medical Branch, Galveston, TX 77550, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nittaya","family":"Khakhum","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Melioidosis","volume":"4","author":"Wiersinga","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2807\/esm.10.03.00528-en","article-title":"Bioterrorism, Glanders and melioidosis","volume":"10","author":"Cheng","year":"2005","journal-title":"Euro Surveill."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/microbiolspec.BAI-0023-2019","article-title":"Shigella pathogenesis: New insights through advanced methodologies","volume":"7","author":"Schnupf","year":"2019","journal-title":"Microbiol. Spectr."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Brunette, G.W., and Nemhauser, J.B. (2020). CDC Yellow Book 2020: Health Information for International Travel. CDC Yellow Book 2020: Health Information for International Travel, Centers for Disease Control and Prevention.","DOI":"10.1093\/med\/9780190928933.003.0002"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"15008","DOI":"10.1038\/nmicrobiol.2015.8","article-title":"Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis","volume":"1","author":"Limmathurotsakul","year":"2016","journal-title":"Nat. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0140-6736(17)33296-8","article-title":"Shigellosis","volume":"391","author":"Kotloff","year":"2018","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/trstmh\/trx031","article-title":"Gastrointestinal tract involvement in melioidosis","volume":"111","author":"Teparrukkul","year":"2017","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"610421","DOI":"10.1155\/2014\/610421","article-title":"Culturable bacterial microbiota of the stomach of Helicobacter pylori positive and negative gastric disease patients","volume":"2014","author":"Khosravi","year":"2014","journal-title":"Sci. World J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Baker, A.L., Pearson, T., Sahl, J.W., Hepp, C., Price, E.P., Sarovich, D.S., Mayo, M., Tuanyok, A., Currie, B.J., and Keim, P. (2018). Burkholderia pseudomallei distribution in Australasia is linked to paleogeographic and anthropogenic history. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0206845"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e00089-15","DOI":"10.1128\/mSphere.00089-15","article-title":"Phylogenomic Analysis Reveals an Asian Origin for African Burkholderia pseudomallei and Further Supports Melioidosis Endemicity in Africa","volume":"1","author":"Sarovich","year":"2016","journal-title":"mSphere"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1038\/s41598-020-62300-8","article-title":"Whole-genome sequencing of Burkholderia pseudomallei from an urban melioidosis hot spot reveals a fine-scale population structure and localised spatial clustering in the environment","volume":"10","author":"Rachlin","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.mib.2015.11.007","article-title":"Intracellular replication of the well-armed pathogen Burkholderia pseudomallei","volume":"29","author":"Willcocks","year":"2016","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_13","first-page":"1","article-title":"Burkholderia pseudomallei as an Enteric Pathogen: Identification of virulence Factors Mediating Gastrointestinal Infection","volume":"89","author":"Tapia","year":"2020","journal-title":"Infect. Immun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1586\/14787210.2014.970634","article-title":"Melioidosis: Molecular aspects of pathogenesis","volume":"12","author":"Stone","year":"2014","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1128\/JB.01455-10","article-title":"Identification of motifs of Burkholderia pseudomallei BimA required for intracellular motility, actin binding, and actin polymerization","volume":"193","author":"Sitthidet","year":"2011","journal-title":"J. Bacteriol."},{"key":"ref_16","first-page":"1","article-title":"The Role of the Type III Secretion System in the Intracellular Lifestyle of Enteric Pathogens","volume":"7","author":"Orth","year":"2019","journal-title":"Microbiol. Spectr."},{"key":"ref_17","first-page":"1","article-title":"The Burkholderia Type VI secretion system 5: Composition, regulation and role in virulence","volume":"10","author":"Lennings","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3201\/eid2106.141480","article-title":"Consensus on the development of vaccines against naturally acquired melioidosis","volume":"21","author":"Limmathurotsakul","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1128\/iai.63.5.1947-1954.1995","article-title":"Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection","volume":"63","author":"Mallett","year":"1995","journal-title":"Infect. Immun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1016\/j.vaccine.2004.12.029","article-title":"Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries","volume":"23","author":"Walker","year":"2005","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/CVI.00683-13","article-title":"Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine","volume":"21","author":"Kaminski","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/CVI.00608-15","article-title":"Evaluation of the safety, tolerability, and immunogenicity of an oral, inactivated whole-cell Shigella flexneri 2a vaccine in healthy adult subjects","volume":"23","author":"Chakraborty","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.3389\/fmicb.2018.02609","article-title":"Cross-Protective Shigella Whole-Cell Vaccine with a Truncated O-Polysaccharide Chain","volume":"9","author":"Kim","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1128\/IAI.66.9.4572-4576.1998","article-title":"Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model","volume":"66","author":"Hartman","year":"1998","journal-title":"Infect. Immun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0092-8674(86)90880-9","article-title":"A genetic determinant required for continuous reinfection of adjacent cells on large plasmid in S. flexneri 2a","volume":"46","author":"Makino","year":"1986","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1016\/j.vaccine.2018.06.063","article-title":"A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei","volume":"36","author":"Frenck","year":"2018","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.4049\/jimmunol.168.10.5240","article-title":"Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium","volume":"168","author":"Khan","year":"2002","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1080\/21645515.2019.1575165","article-title":"A phase I trial of WRSS1, a Shigella sonnei live oral vaccine in Bangladeshi adults and children","volume":"15","author":"Raqib","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_29","first-page":"564","article-title":"Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults","volume":"23","author":"Punnee","year":"2021","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/IAI.67.7.3437-3443.1999","article-title":"Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC","volume":"67","author":"Coster","year":"1999","journal-title":"Infect. Immun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1016\/j.vaccine.2008.03.079","article-title":"Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate","volume":"26","author":"McKenzie","year":"2008","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Mitobe, J., Sinha, R., Mitra, S., Nag, D., Saito, N., Shimuta, K., Koizumi, N., and Koley, H. (2017). An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005728"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Harutyunyan, S., Neuhauser, I., Mayer, A., Aichinger, M., Szij\u00e1rt\u00f3, V., Nagy, G., Nagy, E., Girardi, P., Malinoski, F.J., and Henics, T. (2020). Characterization of shigetec, a novel live attenuated combined vaccine against shigellae and etec. Vaccines, 8.","DOI":"10.3390\/vaccines8040689"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/hv.4746","article-title":"Safety and Immunogenicity of CVD 1208S, a Live, Oral \u2206guaBA \u2206sen \u2206set Shigella flexneri 2a Vaccine Grown on Animal-Free Media","volume":"3","author":"Kotloff","year":"2007","journal-title":"Hum. Vaccin."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1128\/iai.64.8.3055-3061.1996","article-title":"Engineered \u2206guaB-A \u2206virG Shigella flexneri 2a strain CVD 1205: Construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine","volume":"64","author":"Noriega","year":"1996","journal-title":"Infect. Immun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/BF00279799","article-title":"Regulation of the gua operon of Escherichia coli by the DnaA protein","volume":"231","author":"Drabble","year":"1992","journal-title":"Mol. Gen. Genet. MGG"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12967-018-1439-1","article-title":"T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans","volume":"16","author":"Toapanta","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"DeLaine, B.C., Wu, T., Grassel, C.L., Shimanovich, A., Pasetti, M.F., Levine, M.M., and Barry, E.M. (2016). Characterization of a multicomponent live, attenuated Shigella flexneri vaccine. Pathog. Dis., 74.","DOI":"10.1093\/femspd\/ftw034"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1128\/iai.59.11.4075-4083.1991","article-title":"Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains","volume":"59","author":"Hartman","year":"1991","journal-title":"Infect. Immun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41541-020-0180-y","article-title":"A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice","volume":"5","author":"Medeiros","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1128\/iai.59.7.2341-2350.1991","article-title":"Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides","volume":"59","author":"Oberhelman","year":"1991","journal-title":"Infect. Immun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1128\/IAI.68.12.6624-6632.2000","article-title":"Isolation and Characterization of a Shigella flexneri Invasin Complex Subunit Vaccine","volume":"68","author":"Turbyfill","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1016\/j.vaccine.2010.06.086","article-title":"Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers","volume":"28","author":"Tribble","year":"2010","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e00583-17","DOI":"10.1128\/mSphere.00583-17","article-title":"Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex","volume":"3","author":"Turbyfill","year":"2018","journal-title":"mSphere"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Jneid, B., Rouaix, A., F\u00e9raudet-Tarisse, C., and Simon, S. (2020). SipD and IpaD induce a cross-protection against Shigella and Salmonella infections. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0008326"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1016\/j.vaccine.2016.08.034","article-title":"Development of recombinant vaccine candidate molecule against Shigella infection","volume":"34","author":"Chitradevi","year":"2016","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fourie, K.R., and Wilson, H.L. (2020). Understanding GroEL and DnaK Stress Response Proteins as Antigens for Bacterial Diseases. Vaccines, 8.","DOI":"10.3390\/vaccines8040773"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Le\u00f3n, Y., Zapata, L., Molina, R.E., Okanovi\u010d, G., G\u00f3mez, L.A., Daza-Castro, C., Flores-Concha, M., Reyes, J.L., and O\u00f1ate, A.A. (2020). Intranasal Immunization of Mice with Multiepitope Chimeric Vaccine Candidate Based on Conserved Autotransporters SigA, Pic and Sap, Confers Protection against Shigella flexneri. Vaccines, 8.","DOI":"10.3390\/vaccines8040563"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"12881","DOI":"10.1073\/pnas.1101006108","article-title":"Serine protease autotransporters from Shigella flexneri and pathogenic Escherichia coli target a broad range of leukocyte glycoproteins","volume":"108","author":"Wahid","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2958.2000.02008.x","article-title":"The outer membrane protein, antigen 43, mediates cell-to-cell interactions within Escherichia coli biofilms","volume":"37","author":"Danese","year":"2000","journal-title":"Mol. Microbiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1016\/j.vaccine.2013.05.100","article-title":"Outer membrane protein A (OmpA) from Shigella flexneri 2a: A promising subunit vaccine candidate","volume":"31","author":"Pore","year":"2013","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Pore, D., Mahata, N., Pal, A., and Chakrabarti, M.K. (2011). Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0022663"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10989-020-10153-0","article-title":"EpiMix Based Novel Vaccine Candidate for Shigella: Evidence of Prophylactic Immunity in Balb\/c Mice","volume":"27","author":"Padh","year":"2021","journal-title":"Int. J. Pept. Res. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1016\/j.vaccine.2018.06.037","article-title":"Cyclic OmpC peptidic epitope conjugated to tetanus toxoid as a potential vaccine candidate against shigellosis","volume":"36","author":"Witkowska","year":"2018","journal-title":"Vaccine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/infdis\/157.5.1068","article-title":"Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an israeli military population","volume":"157","author":"Cohen","year":"1988","journal-title":"J. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1128\/jcm.27.1.162-167.1989","article-title":"Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections","volume":"27","author":"Cohen","year":"1989","journal-title":"J. Clin. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1073\/pnas.0500044102","article-title":"Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli","volume":"102","author":"Feldman","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1126\/science.298.5599.1790","article-title":"N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli","volume":"298","author":"Wacker","year":"2002","journal-title":"Science"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific-polysaccharide conjugates in 1 to 4 year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/CVI.00224-16","article-title":"Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: A Single-Blind, Randomized Phase I Study","volume":"23","author":"Riddle","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"103310","DOI":"10.1016\/j.ebiom.2021.103310","article-title":"Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection","volume":"66","author":"Talaat","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1016\/j.vaccine.2015.06.102","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study","volume":"33","author":"Hatz","year":"2015","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(20)30488-6","article-title":"Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: A phase 1, dose-escalating, single-blind, randomised, placebo-controlled study","volume":"21","author":"Cohen","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2021.07.001","article-title":"Glycoconjugation of Shigella flexneri type 2a O-polysaccharide with CRM(197) as a potential vaccine candidate for shigellosis","volume":"72","author":"Narayana","year":"2021","journal-title":"Biologicals"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6695","DOI":"10.1016\/j.vaccine.2018.09.052","article-title":"Evaluation of a conjugate vaccine platform against enterotoxigenic Escherichia coli (ETEC), Campylobacter jejuni and Shigella","volume":"36","author":"Laird","year":"2018","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3389\/fmicb.2017.01053","article-title":"Outer Membrane Vesicles (OMVs) of Gram-negative Bacteria: A Perspective Update","volume":"8","author":"Jan","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.vaccine.2013.05.001","article-title":"Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis","volume":"31","author":"Mitra","year":"2013","journal-title":"Vaccine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1016\/j.vaccine.2011.08.121","article-title":"Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice","volume":"29","author":"Camacho","year":"2011","journal-title":"Vaccine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1099\/jmm.0.000527","article-title":"Effective protection of mice against Shigella flexneri with a new self-adjuvant multicomponent vaccine","volume":"66","author":"Pastor","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e0096821","DOI":"10.1128\/AEM.00968-21","article-title":"Outer membrane vesicles derived from Salmonella Typhimurium can deliver Shigella flexneri 2a O-polysaccharide antigen to prevent Shigella flexneri 2a infection in mice","volume":"87","author":"Tian","year":"2021","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Micoli, F., Alfini, R., Di Benedetto, R., Necchi, F., Schiavo, F., Mancini, F., Carducci, M., Palmieri, E., Balocchi, C., and Gasperini, G. (2020). GMMA Is a Versatile Platform to Design Effective Multivalent Combination Vaccines. Vaccines, 8.","DOI":"10.3390\/vaccines8030540"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Berlanda Scorza, F., Colucci, A.M., Maggiore, L., Sanzone, S., Rossi, O., Ferlenghi, I., Pesce, I., Caboni, M., Norais, N., and Di Cioccio, V. (2012). High yield production process for Shigella outer membrane particles. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035616"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Gerke, C., Colucci, A.M., Giannelli, C., Sanzone, S., Vitali, C.G., Sollai, L., Rossi, O., Martin, L.B., Auerbach, J., and Di Cioccio, V. (2015). Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134478"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ebiom.2017.07.013","article-title":"Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results from Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe","volume":"22","author":"Launay","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Raso, M.M., Gasperini, G., Alfini, R., Schiavo, F., Aruta, M.G., Carducci, M., Forgione, M.C., Martini, S., Cescutti, P., and Necchi, F. (2020). GMMA and Glycoconjugate Approaches Compared in Mice for the Development of a Vaccine against Shigella flexneri Serotype. Vaccines, 8.","DOI":"10.3390\/vaccines8020160"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1359-6446(03)02689-8","article-title":"Reverse vaccinology","volume":"8","author":"Mora","year":"2003","journal-title":"Drug Discov. Today"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00253-020-11054-4","article-title":"Identification and evaluation of novel vaccine candidates against Shigella flexneri through reverse vaccinology approach","volume":"105","author":"Hajialibeigi","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7774\/cevr.2020.9.1.15","article-title":"Reverse vaccinology approach for the identification and characterization of outer membrane proteins of Shigella flexneri as potential cellular-and antibody-dependent vaccine candidates","volume":"9","author":"Leow","year":"2020","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-020-00824-4","article-title":"The identification of novel immunogenic antigens as potential Shigella vaccine components","volume":"13","author":"Liang","year":"2021","journal-title":"Genome Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/j.ijid.2009.12.009","article-title":"Production and immunogenicity of recombinant ferric enterobactin protein (FepA)","volume":"14","author":"Baghal","year":"2010","journal-title":"Int. J. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.biologicals.2017.08.004","article-title":"Towards a peptide-based vaccine against Shigella sonnei: A subtractive reverse vaccinology based approach","volume":"50","author":"Baseer","year":"2017","journal-title":"Biologicals"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CVI.00181-17","article-title":"Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a","volume":"24","author":"Dharmasena","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/infdis\/131.5.553","article-title":"Isolation and Characterization of Gal E Mutant Ty 21a of Salmonella typhi: A Candidate Strain for a Live, Oral Typhoid Vaccine","volume":"131","author":"Germanier","year":"1975","journal-title":"J. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1128\/iai.34.3.746-750.1981","article-title":"Construction of a potential bivalent vaccine strain: Introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain","volume":"34","author":"Formal","year":"1981","journal-title":"Infect. Immun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/infdis\/149.2.133","article-title":"Safety and antigenicity of typhoid-Shigella sonnei vaccine (strain 5076-1C)","volume":"149","author":"Tramont","year":"1984","journal-title":"J. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/infdis\/jiw528","article-title":"Development of a Live Attenuated Bivalent Oral Vaccine Against Shigella sonnei Shigellosis and Typhoid Fever","volume":"215","author":"Wu","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"ftw098","DOI":"10.1093\/femspd\/ftw098","article-title":"Stable expression of Shigella dysenteriae serotype 1 O-antigen genes integrated into the chromosome of live Salmonella oral vaccine vector Ty21a","volume":"74","author":"Dharmasena","year":"2016","journal-title":"Pathog. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/jam.13353","article-title":"Immunization with r-Lactococcus lactis expressing outer membrane protein A of Shigella dysenteriae type-1: Evaluation of oral and intranasal route of administration","volume":"122","author":"Yagnik","year":"2017","journal-title":"J. Appl. Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1016\/j.vaccine.2019.04.053","article-title":"Oral immunization with LacVax\u00ae OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model","volume":"37","author":"Yagnik","year":"2019","journal-title":"Vaccine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"106617","DOI":"10.1016\/j.intimp.2020.106617","article-title":"Heterologous expression of Intimin and IpaB fusion protein in Lactococcus lactis and its mucosal delivery elicit protection against pathogenicity of Escherichia coli O157 and Shigella flexneri in a murine model","volume":"85","author":"Sagi","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1016\/j.vaccine.2014.08.035","article-title":"Comparison of the protective effects of killed Burkholderia pseudomallei and CpG oligodeoxynucleotide against live challenge","volume":"32","author":"Puangpetch","year":"2014","journal-title":"Vaccine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1016\/j.vaccine.2011.05.009","article-title":"Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity","volume":"29","author":"Henderson","year":"2011","journal-title":"Vaccine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1016\/j.vaccine.2009.05.040","article-title":"Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders","volume":"27","author":"Smither","year":"2009","journal-title":"Vaccine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2164-6-174","article-title":"Bacterial genome adaptation to niches: Divergence of the potential virulence genes in three Burkholderia species of different survival strategies","volume":"6","author":"Kim","year":"2005","journal-title":"BMC Genom."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/cei.13286","article-title":"Novel multi-component vaccine approaches for Burkholderia pseudomallei","volume":"196","author":"Morici","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0035-9203(08)70022-1","article-title":"Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle","volume":"102","author":"Breitbach","year":"2008","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1128\/IAI.00915-13","article-title":"Correlates of Immune Protection following Cutaneous Immunization with an Attenuated Burkholderia pseudomallei Vaccine","volume":"81","author":"Silva","year":"2013","journal-title":"Infect. Immun."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Amemiya, K., Dankmeyer, J.L., Biryukov, S.S., Trevi\u00f1o, S.R., Klimko, C.P., Mou, S.M., Fetterer, D.P., Garnes, P.G., Cote, C.K., and Worsham, P.L. (2019). Deletion of Two Genes in Burkholderia pseudomallei MSHR668 That Target Essential Amino Acids Protect Acutely Infected BALB\/c Mice and Promote Long Term Survival. Vaccines, 7.","DOI":"10.3390\/vaccines7040196"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1128\/IAI.01240-06","article-title":"Development of signature-tagged mutagenesis in Burkholderia pseudomallei to identify genes important in survival and pathogenesis","volume":"75","author":"Cuccui","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_100","first-page":"123","article-title":"Construction and characterization of an unmarked aroC deletion mutant of Burkholderia pseudomallei strain A2","volume":"40","author":"Srilunchang","year":"2009","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1099\/0022-1317-51-7-539","article-title":"Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis","volume":"51","author":"Atkins","year":"2002","journal-title":"J. Med. Microbiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1086\/508217","article-title":"A Live Experimental Vaccine against Burkholderia pseudomallei Elicits CD4+ T Cell\u2013Mediated Immunity, Priming T Cells Specific for 2 Type III Secretion System Proteins","volume":"194","author":"Haque","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1128\/IAI.05044-11","article-title":"The Burkholderia pseudomallei \u0394asd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice","volume":"79","author":"Norris","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e00102-17","DOI":"10.1128\/IAI.00102-17","article-title":"Antibodies against in vivo-expressed antigens are sufficient to protect against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei","volume":"85","author":"Zimmerman","year":"2017","journal-title":"Infect. Immun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1099\/mic.0.27146-0","article-title":"Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis","volume":"150","author":"Stevens","year":"2004","journal-title":"Microbiology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1128\/IAI.00178-12","article-title":"Role of RelA and SpoT in Burkholderia pseudomallei virulence and immunity","volume":"80","author":"Conejero","year":"2012","journal-title":"Infect. Immun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e00570-18","DOI":"10.1128\/mSphere.00570-18","article-title":"Burkholderia pseudomallei \u0394tonB \u0394hcp1 Live Attenuated Vaccine Strain Elicits Full Protective Immunity against Aerosolized Melioidosis Infection","volume":"4","author":"Khakhum","year":"2019","journal-title":"mSphere"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Khakhum, N., Bharaj, P., Myers, J.N., Tapia, D., Walker, D.H., Endsley, J.J., and Torres, A.G. (2019). Evaluation of Burkholderia mallei \u0394tonB \u0394hcp1 (CLH001) as a live attenuated vaccine in murine models of glanders and melioidosis. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007578"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-021-00333-4","article-title":"Antigen-specific antibody and polyfunctional T cells generated by respiratory immunization with protective Burkholderia \u0394tonB \u0394hcp1 live attenuated vaccines","volume":"6","author":"Khakhum","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/IAI.00328-16","article-title":"Burkholderia mallei CLH001 attenuated vaccine strain is immunogenic and protects against acute respiratory glanders","volume":"84","author":"Hatcher","year":"2016","journal-title":"Infect. Immun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1128\/IAI.00404-07","article-title":"Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis","volume":"75","author":"Harland","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Hara, Y., Mohamed, R., and Nathan, S. (2009). Immunogenic Burkholderia pseudomallei Outer Membrane Proteins as Potential Candidate Vaccine Targets. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006496"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1016\/j.vaccine.2010.05.022","article-title":"Immunization with the recombinant Burkholderia pseudomallei outer membrane protein Omp85 induces protective immunity in mice","volume":"28","author":"Su","year":"2010","journal-title":"Vaccine"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.vaccine.2016.03.088","article-title":"Identification of an OmpW homologue in Burkholderia pseudomallei, a protective vaccine antigen against melioidosis","volume":"34","author":"Casey","year":"2016","journal-title":"Vaccine"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1128\/IAI.01218-10","article-title":"The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei","volume":"79","author":"Burtnick","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.provac.2010.03.013","article-title":"Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge","volume":"2","author":"Whitlock","year":"2010","journal-title":"Procedia Vaccinol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"eaat4615","DOI":"10.1126\/scitranslmed.aat4615","article-title":"Glycoconjugate vaccines: Principles and mechanisms","volume":"10","author":"Rappuoli","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_118","first-page":"381","article-title":"Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machinery","volume":"5","author":"Iwashkiw","year":"2014","journal-title":"Front. Microbiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"392170","DOI":"10.1155\/2014\/392170","article-title":"Protection against experimental melioidosis following immunisation with a lipopolysaccharide-protein conjugate","volume":"2014","author":"Scott","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e00724-17","DOI":"10.1128\/IAI.00724-17","article-title":"Development of subunit vaccines that provide high-level protection and sterilizing immunity against acute inhalational melioidosis","volume":"86","author":"Burtnick","year":"2017","journal-title":"Infect. Immun."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1021\/acs.bioconjchem.5b00525","article-title":"Protection against Experimental Melioidosis with a Synthetic manno-Heptopyranose Hexasaccharide Glycoconjugate","volume":"27","author":"Scott","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1128\/IAI.01847-14","article-title":"Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis","volume":"82","author":"Scott","year":"2014","journal-title":"Infect. Immun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1016\/j.vaccine.2011.08.058","article-title":"A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection","volume":"29","author":"Nieves","year":"2011","journal-title":"Vaccine"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/CVI.00119-14","article-title":"A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis","volume":"21","author":"Nieves","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-021-00281-z","article-title":"Burkholderia pseudomallei OMVs derived from infection mimicking conditions elicit similar protection to a live-attenuated vaccine","volume":"6","author":"Baker","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.provac.2014.07.007","article-title":"Evaluation of a Burkholderia pseudomallei Outer Membrane Vesicle Vaccine in Nonhuman Primates","volume":"8","author":"Petersen","year":"2014","journal-title":"Procedia Vaccinol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e00206-17","DOI":"10.1128\/CVI.00206-17","article-title":"Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei","volume":"24","author":"Muruato","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.micpath.2018.09.033","article-title":"Reverse vaccinology and subtractive genomics-based putative vaccine targets identification for Burkholderia pseudomallei Bp1651","volume":"125","author":"Hizbullah","year":"2018","journal-title":"Microb. Pathog."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e0122721","DOI":"10.1128\/mBio.01227-21","article-title":"Multicomponent Gold-Linked Glycoconjugate Vaccine Elicits Antigen-Specific Humoral and Mixed TH1-TH17 Immunity, Correlated with Increased Protection against Burkholderia pseudomallei","volume":"12","author":"Tapia","year":"2021","journal-title":"mBio"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.provac.2009.07.005","article-title":"Vaxign: A web-based vaccine target design program for reverse vaccinology","volume":"1","author":"Xiang","year":"2009","journal-title":"Procedia Vaccinol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.chembiol.2013.07.010","article-title":"Exploiting the Burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery\/design in structural vaccinology","volume":"20","author":"Gourlay","year":"2013","journal-title":"Chem. Biol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Capelli, R., Peri, C., Villa, R., Nithichanon, A., Conchillo-Sol\u00e9, O., Yero, D., Gagni, P., Chiari, M., Lertmemongkolchai, G., and Cretich, M. (2018). BPSL1626: Reverse and Structural Vaccinology Reveal a Novel Candidate for Vaccine Design against Burkholderia pseudomallei. Antibodies, 7.","DOI":"10.3390\/antib7030026"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1128\/IAI.74.3.1699-1705.2006","article-title":"CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB\/c mice","volume":"74","author":"Chen","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1080\/21505594.2017.1307485","article-title":"Rapid DNA vaccination against Burkholderia pseudomallei flagellin by tattoo or intranasal application","volume":"8","author":"Lankelma","year":"2017","journal-title":"Virulence"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"100002","DOI":"10.1016\/j.jvacx.2018.100002","article-title":"The autotransporter protein BatA is a protective antigen against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei","volume":"1","author":"Lafontaine","year":"2019","journal-title":"Vaccine X"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/11\/1353\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:19:03Z","timestamp":1760167143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/11\/1353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":135,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["pathogens10111353"],"URL":"https:\/\/doi.org\/10.3390\/pathogens10111353","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]}}}